Your browser is no longer supported. Please, upgrade your browser.
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.42 Insider Own0.10% Shs Outstand9.37M Perf Week-2.79%
Market Cap32.31M Forward P/E- EPS next Y-2.91 Insider Trans94.08% Shs Float8.80M Perf Month-18.02%
Income-20.40M PEG- EPS next Q-0.65 Inst Own44.60% Short Float4.02% Perf Quarter-35.39%
Sales- P/S- EPS this Y65.30% Inst Trans- Short Ratio3.81 Perf Half Y-38.31%
Book/sh4.42 P/B0.71 EPS next Y-27.80% ROA-45.30% Target Price20.00 Perf Year-58.68%
Cash/sh3.91 P/C0.80 EPS next 5Y- ROE-49.10% 52W Range2.76 - 11.42 Perf YTD-19.28%
Dividend- P/FCF- EPS past 5Y49.80% ROI- 52W High-72.50% Beta1.17
Dividend %- Quick Ratio12.10 Sales past 5Y- Gross Margin- 52W Low13.77% ATR0.27
Employees12 Current Ratio12.10 Sales Q/Q- Oper. Margin- RSI (14)34.85 Volatility9.13% 7.44%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.40% Profit Margin- Rel Volume0.59 Prev Close3.20
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume92.92K Price3.14
Recom1.50 SMA20-13.95% SMA50-15.53% SMA200-41.01% Volume55,020 Change-1.87%
Apr-27-20Resumed ROTH Capital Buy $24
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Nov-27-07Reiterated Cantor Fitzgerald Buy $14 → $10.50
Aug-10-07Reiterated Cantor Fitzgerald Buy $12 → $14
Jun-04-07Reiterated Needham & Co Buy $9 → $12
Apr-23-07Initiated Lazard Capital Buy $11
Apr-10-07Initiated Cantor Fitzgerald Buy $12
Jan-06-22 07:00AM  
Dec-23-21 07:00AM  
Dec-20-21 02:00AM  
Dec-07-21 05:25AM  
Nov-10-21 04:05PM  
Nov-05-21 09:41AM  
Oct-29-21 07:00AM  
Oct-04-21 09:00AM  
Sep-08-21 07:00AM  
Aug-11-21 04:05PM  
Aug-03-21 07:00AM  
Jul-13-21 07:00AM  
Jul-07-21 07:15AM  
May-17-21 08:30PM  
May-12-21 04:05PM  
May-05-21 07:00AM  
Mar-16-21 04:05PM  
Mar-15-21 07:16AM  
Mar-12-21 08:30AM  
Mar-11-21 04:01PM  
Feb-25-21 04:05PM  
Feb-19-21 07:00AM  
Feb-10-21 07:00AM  
Feb-01-21 10:05PM  
Jan-11-21 07:46AM  
Dec-30-20 07:00AM  
Dec-22-20 08:00AM  
Dec-21-20 07:00AM  
Nov-11-20 04:05PM  
Nov-05-20 09:29AM  
Oct-26-20 08:26AM  
Oct-23-20 04:30PM  
Oct-05-20 07:00AM  
Sep-21-20 07:00AM  
Aug-16-20 04:26AM  
Aug-12-20 04:05PM  
Aug-05-20 07:00AM  
Jul-28-20 11:46AM  
Jul-13-20 07:00AM  
May-21-20 09:22AM  
May-12-20 04:05PM  
May-05-20 07:00AM  
Apr-24-20 04:05PM  
Apr-21-20 12:59PM  
Apr-20-20 07:00AM  
Apr-14-20 12:30PM  
Mar-17-20 07:17AM  
Mar-12-20 12:13AM  
Feb-26-20 04:05PM  
Feb-20-20 08:50AM  
Feb-19-20 07:00AM  
Feb-10-20 08:53AM  
Feb-03-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-11-19 06:13AM  
Dec-09-19 07:00AM  
Dec-04-19 07:18AM  
Nov-13-19 04:05PM  
Nov-07-19 07:00AM  
Nov-06-19 09:00AM  
Oct-12-19 09:44AM  
Sep-23-19 07:00AM  
Sep-09-19 07:00AM  
Sep-04-19 07:00AM  
Sep-03-19 12:30PM  
Aug-28-19 12:34PM  
Aug-13-19 04:05PM  
Aug-11-19 03:46PM  
Aug-07-19 07:00AM  
Jul-22-19 07:00AM  
Jul-04-19 06:49AM  
Jun-26-19 02:59PM  
May-24-19 12:50PM  
May-14-19 04:05PM  
May-08-19 07:00AM  
Apr-29-19 09:55AM  
Apr-09-19 11:05AM  
Apr-01-19 07:00AM  
Mar-27-19 04:05PM  
Mar-26-19 12:46PM  
Mar-25-19 07:00AM  
Mar-20-19 07:00AM  
Mar-13-19 07:00AM  
Mar-05-19 07:00AM  
Feb-05-19 07:00AM  
Jan-24-19 07:25AM  
Jan-07-19 07:00AM  
Jan-03-19 11:11PM  
Dec-27-18 07:00AM  
Dec-25-18 02:25PM  
Dec-04-18 07:35AM  
Nov-13-18 07:54AM  
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARKER SAM LDirectorNov 30Sale3.5712433,374Dec 02 04:07 PM
Rombotis Spiro GeorgePresident and CEONov 18Buy4.504,00018,0004,988Nov 22 04:05 PM
BARKER SAM LDirectorAug 24Buy5.001,0005,0003,386Aug 25 04:16 PM